1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.

The discovery of new highly potent and selective triple reuptake inhibitors is reported. The new classes of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes are described together with detailed SAR. Appropriate decoration of the scaffolds was achieved with the help of a triple reuptake inhibitor pharmacophore model detailed here. Selected derivatives showed good oral bioavailability (>30%) and brain penetration (B/B > 4) in rats associated with high in vitro potency and selectivity at SERT, NET, and DAT. Among these compounds, microdialysis and in vivo experiments confirm that derivative 15 has an appropriate developability profile to be considered for further progression.

[1]  M. Hascöet,et al.  Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice , 2009, Psychopharmacology.

[2]  C. Nemeroff,et al.  Emerging targets for antidepressant therapies. , 2009, Current opinion in chemical biology.

[3]  S. Kulkarni,et al.  Current investigational drugs for major depression , 2009 .

[4]  Saul Jaime-Figueroa,et al.  Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[5]  P. Carlier,et al.  Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS) , 2008, Journal of Pharmacology and Experimental Therapeutics.

[6]  Brian Lord,et al.  In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. , 2008, European journal of pharmacology.

[7]  P. Skolnick,et al.  Triple uptake inhibitors: therapeutic potential in depression and beyond , 2007, Expert opinion on investigational drugs.

[8]  C. Nemeroff.  The burden of severe depression: a review of diagnostic challenges and treatment alternatives. , 2007, Journal of psychiatric research.

[9]  G. Papakostas.  Dopaminergic-based pharmacotherapies for depression , 2006, European Neuropsychopharmacology.

[10]  C. Heidbreder,et al.  Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex , 2005, Neuroscience Letters.

[11]  Джотам Уодсворт Коэ,et al.  Preparation of 3-azabicyclo [3.1.0] hexane , 2004 .

[12]  M. Millan.  The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. , 2004, European journal of pharmacology.

[13]  Julio Licinio,et al.  From monoamines to genomic targets: a paradigm shift for drug discovery in depression , 2004, Nature Reviews Drug Discovery.

[14]  J. Hyttel,et al.  Pharmacology in vivo of the phenylindan derivative, lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain , 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  A. Janowsky,et al.  "Broad spectrum" antidepressants: is more better for the treatment of depression? , 2003, Life sciences.

[16]  A. Janowsky,et al.  Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. , 2003, European journal of pharmacology.

[17]  Йерген Шель-Крюгер,et al.  Tropane derivatives, their preparation and use , 1997 .

[18]  G. Rigdon,et al.  Potentiation of the behavioral effects of 5‐hydroxytryptophan by BW 1370U87, a selective monoamine oxidase‐A inhibitor , 1992 .

[19]  G. Martin,et al.  Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation. , 1984, The Journal of pharmacology and experimental therapeutics.